GHK-Cu: EMA vs FDA Regulatory Approach Explained

What is the FDA's position on GHK-Cu?

No FDA-approved drug is known to contain GHK-Cu. FDA's records treat it as a nominated bulk drug substance for compounding, not as an approved medicine [3]. The approved copper product it is sometimes confused with is copper histidinate (Zycubo), approved January 12, 2026 for Menkes disease in children, which is a different compound [3][6].

Why a cream is a cosmetic and an injection is not

Cosmetics and cosmetic ingredients other than color additives do not need FDA approval before they are sold, which is how copper peptide serums and creams reach the market [1]. Intended use decides the category: claims to treat disease or to change the structure or function of the body make a product a drug [1]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [1].

Compounding status: category 1 for creams, withdrawn nomination for injections

Non-injectable GHK-Cu, listed as GHK-Cu except for injectable routes of administration, is in category 1, the group under evaluation for the pharmacy bulks list; FDA says it generally does not intend to act against compounders for category 1 substances if its guidance conditions are met [3][4]. The listing moved in 2026: it came off category 1 on April 22 when the nominations were withdrawn, a nominator clarified on May 5 that only the injectable route was withdrawn, and FDA added non-injectable GHK-Cu back, updating the list on May 14, 2026 [3][4]. FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether GHK-Cu belongs on the bulks list; no vote has taken place [3].

Injectable GHK-Cu appears in FDA's table of nominated-but-withdrawn bulk substances, page content dated 04/22/2026. There FDA writes that compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [2]. Injectable GHK-Cu is not in category 1 and appears in no category on FDA's current list [2][3]. GHK-Cu is also absent from FDA's list for outsourcing facilities, updated March 21, 2025 [7], and is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [8]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [5].

Where does the EMA stand?

This page documents US regulation only. The FDA information above does not establish any EMA or EU-wide decision about GHK-Cu.

How strong are the human data?

A randomized trial of 13 patients who had carbon dioxide laser resurfacing found no significant difference in redness resolution, wrinkles or overall skin quality on computer analysis and blinded assessment; a patient questionnaire favoured GHK-Cu (P=.04) [9]. A randomized evaluator-blinded trial in 86 evaluable patients found a 0.4% tripeptide copper complex cream no different from an inert vehicle for venous ulcer size, while silver sulfadiazine 1% reduced it [10]. A 2026 systematic review that kept 64 records published between 2005 and 2026 describes the human literature as thin and fragmented, with most randomized trials small and run on facial cosmetic creams [11]. For injectables, FDA points to limited human data [2].